stoxline Quote Chart Rank Option Currency Glossary
  
Oculis Holding AG (OCS)
21.68  1.98 (10.05%)    12-05 16:00
Open: 19.81
High: 21.68
Volume: 213,540
  
Pre. Close: 19.7
Low: 19.81
Market Cap: 1,135(M)
Technical analysis
2025-12-05 4:49:45 PM
Short term     
Mid term     
Targets 6-month :  25.32 1-year :  29.57
Resists First :  21.68 Second :  25.32
Pivot price 19.36
Supports First :  19.8 Second :  18.64
MAs MA(5) :  19.63 MA(20) :  19.33
MA(100) :  18.65 MA(250) :  0
MACD MACD :  0 Signal :  -0.2
%K %D K(14,3) :  71.4 D(3) :  44.6
RSI RSI(14): 71.9
52-week High :  23.07 Low :  14
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ OCS ] has closed Bollinger Bands are 18.6% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 21.71 - 21.8 21.8 - 21.89
Low: 19.61 - 19.69 19.69 - 19.78
Close: 21.53 - 21.69 21.69 - 21.85
Company Description

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops novel topical treatments for ophthalmic diseases for both back- and front-of-the-eye. The company's lead candidate is OCS-01, a topical dexamethasone formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for keratoconjunctivitis sicca, or dry eye disease; and OCS-05, a novel neuroprotective agent for acute optic neuritis and other neuro-ophtha disorders, such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The company is based in Zug, Switzerland.

Headline News

Sat, 06 Dec 2025
Oculis (NASDAQ:OCS) Trading 7% Higher - Here's What Happened - MarketBeat

Sat, 06 Dec 2025
Assessing Oculis Holding (NasdaqGM:OCS) Valuation Following $9.4 Million Shelf Registration Completion - simplywall.st

Sat, 06 Dec 2025
Oculis (Nasdaq: OCS) accelerates Privosegtor into registrational optic neuropathy trials - Stock Titan

Wed, 03 Dec 2025
LifeSci Capital Initiates Coverage of Oculis Holding (OCS) with Outperform Recommendation - Nasdaq

Wed, 03 Dec 2025
Oculis Holding AG (OCS) Upgraded to Buy: Here's What You Should Know - sharewise.com

Wed, 03 Dec 2025
Oculis (NASDAQ: OCS) discloses RSU vesting and settlement by company director - Stock Titan

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Neutral
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Neutral
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 0 (M)
Shares Float 58 (M)
Held by Insiders 3.994e+007 (%)
Held by Institutions 5.7 (%)
Shares Short 65 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS -7.779e+007
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin 0 %
Operating Margin -8 %
Return on Assets (ttm) 352.2 %
Return on Equity (ttm) -33.4 %
Qtrly Rev. Growth 791000 %
Gross Profit (p.s.) 89.28
Sales Per Share -658.5
EBITDA (p.s.) -3.91214e+008
Qtrly Earnings Growth -2.7 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow -59 (M)
Stock Valuations
PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales -0.04
Price to Cash Flow 1.21
Stock Dividends
Dividend 0
Forward Dividend 37250
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android